Lower May Not Be Better
Systolic Blood Pressure And Risk Of Major Adverse Limb Events In Patients With Symptomatic Peripheral Artery Disease After Revascularization: Insights From VOYAGER PAD

Cullen E. Buchanan, MD, Michael Szarek, Eike Sebastian Debus, MD, PhD, Manesh R. Patel, MD, Mark R. Nehler, MD, Sonia S. Anand, MD, Connie N. Hess, MD, MHS, Judith Hsia, MD, Eva Muehlhofer, MD, Lloyd P. Haskell, MD, MBA, Scott D. Berkowitz, MD, Rupert M. Bauersachs, MD, Marc P. Bonaca, MD, MPH

Cullen Buchanan, MD
Disclosures

Cullen Buchanan, MD\textsuperscript{1,2}: No conflicts/disclosures

\textsuperscript{1}University of Colorado Anschutz School of Medicine
\textsuperscript{2}Medical College of Wisconsin
Goals

1. Emphasize a multimodal approach to the treatment of symptomatic peripheral artery disease (PAD), including blood pressure (BP) and lower extremity revascularization (LER)

2. Highlight the current uniform approach to blood pressure management

3. Consider an individualized approach to BP management in patients with symptomatic PAD in the first month following LER
Background

- PAD affects >200 million individuals worldwide

- Hypertension (HTN) is a significant risk factor for major adverse cardiovascular events (MACE) and there are well established optimal BP targets for MACE prevention

- Less intensive BP control is allowed to minimize end organ damage in certain settings such as acute ischemic stroke and acute kidney injury

2017 ACC/AHA Hypertension Guidelines

9.5. Peripheral Artery Disease

Recommendation for Treatment of Hypertension in Patients With PAD

References that support the recommendation are summarized in Online Data Supplement 45.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-NR</td>
<td>1. Adults with hypertension and PAD should be treated similarly to patients with hypertension without PAD.</td>
</tr>
</tbody>
</table>
Background

- Re-analysis of the ALLHAT trial investigated the effect of different antihypertensive medications on cardiovascular events, including PAD related events.

- Systolic blood pressure (SBP) <120mmHg was associated with a 26% higher rate of major adverse limb events (MALE) in stable patients with PAD.
VOYAGER PAD TRIAL DESIGN

6564 Patients with Symptomatic Lower Extremity PAD Undergoing Peripheral Revascularization

**Screening Phase:** BP measured at 30 days prior to LER up to 10 days after LER

**Randomization** after LER

**Treatment Phase:** BP measured at baseline, 1, 3, 6, 12 and every 6 months after LER

- **Rivaroxaban 2.5 mg twice daily + Aspirin 100mg once daily**
- **Placebo + Aspirin 100mg once daily**

**Baseline BP** to include screening and randomization visits.

**Avg BP at 1 month following LER used to assess risk for MACE and MALE**

**Follow up BP at 3, 6, 12, and every 6 months after LER**
- Median follow up 28 months

**Primary Composite Endpoint:** Time to first event of MACE or MALE.
Risk of MACE and MALE by SBP 1 Month After LER

*Every 5mmHg decrease in SBP <120mmHg is associated with 7% increase of MALE

*Splines estimated in proportional hazard models with adjustment for treatment assignments. Not adjusted for other possible confounders.
Risk of MALE by SBP 1 Month After LER Stratified by Index Revascularization Type

Risk of MALE based on SBP 1 month following Surgical LER

Risk of MALE based on SBP 1 month following Endovascular LER

*Splines estimated in proportional hazard models with adjustment for treatment assignments. Not adjusted for other possible confounders.*
Summary & Conclusions

- Patients with PAD are at an increased risk of MALE.

- An inverse relationship between systolic blood pressure at 1 month following LER and risk for MALE was observed, consistent with analyses from ALLHAT.

- The pattern appeared consistent regardless of index revascularization type.

- Further investigation is needed to determine whether the higher rates of MALE that were associated with lower systolic blood pressures was independent of other risk factors and whether there is a true causal relationship between BP and MALE in PAD.
THANK YOU!